vTv Therapeutics (NASDAQ:VTVT) Given “Sell (D-)” Rating at Weiss Ratings

Weiss Ratings reiterated their sell (d-) rating on shares of vTv Therapeutics (NASDAQ:VTVT) in a research report report published on Tuesday,Weiss Ratings reports.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price on shares of vTv Therapeutics in a research report on Wednesday, August 13th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, vTv Therapeutics has an average rating of “Hold” and a consensus price target of $35.50.

vTv Therapeutics Price Performance

Shares of NASDAQ:VTVT opened at $22.10 on Tuesday. The business’s 50-day moving average is $19.08 and its 200 day moving average is $18.09. vTv Therapeutics has a 1 year low of $12.62 and a 1 year high of $26.99. The firm has a market capitalization of $87.07 million, a P/E ratio of -7.08 and a beta of 0.67.

vTv Therapeutics (NASDAQ:VTVT) last announced its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.07).

Institutional Investors Weigh In On vTv Therapeutics

A hedge fund recently bought a new stake in vTv Therapeutics stock. Connective Capital Management LLC acquired a new stake in vTv Therapeutics Inc. (NASDAQ:VTVT) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,377 shares of the biotechnology company’s stock, valued at approximately $162,000. Connective Capital Management LLC owned 0.29% of vTv Therapeutics at the end of the most recent quarter. 17.51% of the stock is currently owned by institutional investors and hedge funds.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.